Observation | Jotup

MADD's "Power of Parents Handbook" Helps Parents In the Fight Against Underage Drinking and Impaired Driving

Retrieved on:

Tuesday, April 9, 2024

Research, Pennsylvania State University, Nationwide Mutual Insurance Company, Legal drinking age, Medicine, Mother, Crash, Observation, Death, Volunteering, Life, Drinking, Nationwide, CDC, Handbook, Safety, NOT, NHTSA

IRVING, Texas, April 8, 2024 /PRNewswire-PRWeb/ -- The Power of Parents Handbook developed by Mothers Against Drunk Driving® (MADD) and Robert Turrisi, Ph.D., Professor of Biobehavioral Health and Prevention Research Center at Penn State, is helping to equip parents, guardians, and caring adults to have lifesaving conversations with the youth in their lives.

Key Points:

"My collaborative effort with MADD on the Power of Parents is easily the most significant highlight of my career.
Being able to make a difference in the lives of so many families is such a great privilege and honor.
In addition, numerous studies show that kids say their parents are the leading influence on their decisions about drinking.
Parents can download free Power of Parents handbooks for parents of middle school and high school students at http://www.madd.org/powerofparents .

Pacing Toward Progress: Dr. Daniel Corcos' Trailblazing Research Reveals Exercise's Potential to Slow Parkinson's Disease Progression

Retrieved on:

Monday, April 8, 2024

Exercise, Disease, PD, Alzheimer's disease, Risk, Patient, Heart rate, State, Observation, Parkinson's disease, Woman, Cognition, Principal investigator, Urban, Neurodegenerative disease, Pharmaceutical industry

As the second-most common neurodegenerative disease after Alzheimer's disease, PD affects nearly 90,000 individuals annually in the U.S. Globally, over 10 million people are grappling with PD.

Key Points:

As the second-most common neurodegenerative disease after Alzheimer's disease, PD affects nearly 90,000 individuals annually in the U.S. Globally, over 10 million people are grappling with PD.
Moreover, men are 1.5 times more likely to develop Parkinson's disease than women.
Three recent studies, suggests that endurance exercise may offer a significant breakthrough in Parkinson's treatment in that the suggest that exercising at 80% of maximum heart rate may slow disease progression.
Dr. Corcos underscores the indispensable role of aerobic exercise in Parkinson's treatment, citing evidence suggesting its potential to slow disease progression.

Special edition vinyl albums cause some fans delight – but others suspect a cynical marketing ploy

Retrieved on:

Tuesday, April 9, 2024

In fact, physical sales are so healthy that HMV has risen from the ashes and returned to its flagship store on Oxford Street.

Key Points:

In fact, physical sales are so healthy that HMV has risen from the ashes and returned to its flagship store on Oxford Street.
According to Lawrence Montgomery, the managing director of Rough Trade record stores, Swift owes her success in part to appealing to a younger contingent of fans by turning her albums into collectables.
She has done this through the release of multiple alternate album covers or disc colours.
A few days later, another special edition, with a fourth bonus track, was made available.

The special ones

Ariana Grande’s Eternal Sunshine album, released in March 2024 came in five CD and six vinyl variants, as well as a deluxe edition.
Perhaps the most troubling aspect of all this is how children are being targeted as consumers of these expensive products.
Researchers have observed that Swift’s 2019 album, Lover, was focused on a “tween identity”.

Cross-generational collecting

Millennials like me are also being suckered in by the allure of special editions.
I’m a Beatles and Pink Floyd fan, and I’m not oblivious to the numerous re-releases both acts have been party to over the decades.
I have three copies of Abbey Road, three White Albums, three versions of Let it Be, and more editions of McCartney than anyone rightfully needs.
And yes, I’ve bought them, even though I already own more than one copy of each.

Looking for something good? Cut through the noise with a carefully curated selection of the latest releases, live events and exhibitions, straight to your inbox every fortnight, on Fridays. Sign up here.
Glenn Fosbraey does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

Body armour made from silk is being developed – but this apparently cutting-edge idea is centuries old

Retrieved on:

Tuesday, April 9, 2024

Impenetrability, Gene, Face, The Tombstone Epitaph, Steel, Calculus, History, Tearing, Observation, Manuscript, Nature, Bleeding, Invention, Skull, Movement, Catholic Church, Silk

The researchers modified the genes of silkworms to make them produce spider silk instead of their own silk.

Key Points:

The researchers modified the genes of silkworms to make them produce spider silk instead of their own silk.
Harnessing the properties of spider silk has been a longstanding aim because the material is as strong as steel, yet also highly elastic.
However, the idea of using silk to make bulletproof vests is not a new idea.

Five years later, Dr Goodfellow published further observations in “Notes on the Impenetrability of Silk to Bullets” in a journal called The Southern California Practioneer.
Using Goodfellow’s findings, the Catholic priest Casimir Zeglen (1869–1927) would later invent a silk bulletproof vest.
But the potential for silk as ballistic body armour had been recognised more than two centuries earlier, by Leibniz.
Instead, he thought silk was the most promising material for a bulletproof fabric due to being lightweight, flexible, and strong.
His idea for silk bulletproof clothing therefore did not get off the drawing board.

Lloyd Strickland does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101

Retrieved on:

Friday, March 22, 2024

Ocular Pain Relief showed statistically significant improvement as early as day 15 and the benefit was durable throughout the trial.

Key Points:

Ocular Pain Relief showed statistically significant improvement as early as day 15 and the benefit was durable throughout the trial.
Tear Film Break-up Time showed statistically significant improvement as early as day 15 with the benefit durable for the remainder of the trial.
Burning/Stinging, and Blurred Vision improved as early as day 15 and the benefit remained durable throughout the trial.
Significant improvements were observed across multiple symptoms as measured in a daily symptom diary including pain, burning/stinging, eye dryness and itching within the first two weeks of treatment.

Pyxis Oncology Provides Corporate Update and Reports Financial Results for Fourth Quarter and Full Year 2023

Retrieved on:

Thursday, March 21, 2024

BOSTON, March 21, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today reported financial results for the year and quarter ended December 31, 2023, and provided a corporate update.

Key Points:

BOSTON, March 21, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today reported financial results for the year and quarter ended December 31, 2023, and provided a corporate update.
Approximately 54% of subjects have experienced grade 2, and 6% of subjects have experienced grade 3 treatment emergent adverse events (TEAEs).
As of December 31, 2023, Pyxis Oncology had cash and cash equivalents, including restricted cash, and short-term investments of $120.8 million.
As of March 20, 2024, the outstanding number of shares of Common Stock of Pyxis Oncology was 58,133,375.

Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on:

Thursday, March 21, 2024

In October 2023, Cabaletta received Investigational New Drug (IND) application clearance from the U.S. Food and Drug Administration (FDA) for the Phase 1/2 RESET-SSc trial.

Key Points:

In October 2023, Cabaletta received Investigational New Drug (IND) application clearance from the U.S. Food and Drug Administration (FDA) for the Phase 1/2 RESET-SSc trial.
In November 2023, Cabaletta announced that its IND application for CABA-201 was allowed to proceed by the FDA for the Phase 1/2 RESET-MG trial.
Cabaletta anticipates reporting initial clinical data from the Phase 1/2 RESET-MG trial in the second half of 2024.
As of December 31, 2023, Cabaletta had cash, cash equivalents and short-term investments of $241.2 million, compared to $106.5 million as of December 31, 2022.

Nykode Therapeutics Announces Topline Conclusions Affirming Prolonged Clinical Benefits from Matured Survival Data in Phase 2 C-02 Trial in Advanced Cervical Cancer

Retrieved on:

Thursday, March 21, 2024

Head, Survival, Immunotherapy, Cervical cancer, Patient, Research, Observation, ASA, Pharmaceutical industry

Updated C-02 survival data support the accelerated development of VB10.16, including the potential US pivotal trial C-04 in recurrent or metastatic cervical cancer, and advancing of the program into earlier stages of cervical cancer and expanding into head and neck cancer.

Key Points:

Updated C-02 survival data support the accelerated development of VB10.16, including the potential US pivotal trial C-04 in recurrent or metastatic cervical cancer, and advancing of the program into earlier stages of cervical cancer and expanding into head and neck cancer.
Nykode will present detailed data in a future scientific publication and at a forthcoming conference.
The trial investigates the use of Nykode’s wholly-owned off-the-shelf therapeutic cancer vaccine candidate VB10.16 in combination with Roche’s checkpoint inhibitor atezolizumab in patients with recurrent or metastatic HPV16-positive cervical cancer.
Nykode wishes to thank the patients, their families and the investigators for their participation and contribution to the VB-C-02 trial.

Alimera Announces First Patient Randomized in Radiation Retinopathy Trial Being Conducted by the DRCR Retina Network

Retrieved on:

Tuesday, March 19, 2024

Macular edema, Fluocinolone acetonide, Observation, Intravitreal implants, Injection, Risk, Paratriathlon, Patient, Alimera Sciences, Plaque, Cleveland Clinic, Retina, Brachytherapy, Radiation, Physician

ATLANTA, March 19, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces that the first patient has been randomized in the DRCR Retina Network’s Protocol AL. The study is titled, “A Randomized Clinical Trial Evaluating Intravitreal Faricimab (6.0 mg) Injections or Fluocinolone Acetonide (0.19 mg) Intravitreal Implants vs Observation for Prevention of Visual Acuity Loss due to Radiation Retinopathy.”

Key Points:

ATLANTA, March 19, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces that the first patient has been randomized in the DRCR Retina Network’s Protocol AL.
The study is titled, “A Randomized Clinical Trial Evaluating Intravitreal Faricimab (6.0 mg) Injections or Fluocinolone Acetonide (0.19 mg) Intravitreal Implants vs Observation for Prevention of Visual Acuity Loss due to Radiation Retinopathy.”
The study, chaired by Arun Singh, M.D.
(Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio), plans to include 600 participants with primary choroidal melanoma receiving treatment with plaque brachytherapy.
“We are very excited that this study is underway as it has the potential to show ILUVIEN addressing another unmet need affecting the retina,” said Rick Eiswirth, President and Chief Executive Officer of Alimera.

Allogene Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update

Retrieved on:

Thursday, March 14, 2024

These restated financial statements have no impact on the Company’s cash, cash equivalents and marketable investments, cash runway or business operations.

Key Points:

These restated financial statements have no impact on the Company’s cash, cash equivalents and marketable investments, cash runway or business operations.
Research and development expenses were $54.7 million for the fourth quarter of 2023, which includes $7.0 million of non-cash stock-based compensation expense.
General and administrative expenses were $17.2 million for the fourth quarter of 2023, which includes $8.2 million of non-cash stock-based compensation expense.
Allogene will host a live conference call and webcast today at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss financial results and provide a business update.